ARTICLE | Company News
Biogen Idec, Cardiokine deal
November 8, 2010 8:00 AM UTC
Biogen Idec and Cardiokine terminated a 2007 deal to develop and commercialize lixivaptan to treat hyponatremia. Biogen Idec returned all rights to the selective vasopressin 2 (V2) receptor antagoni...